Credit Suisse Group AG (CS)

DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced positive results from the Phase 2 BEACON study evaluating brepocitinib in cutaneous sarcoidosis (CS). CS is a highly morbid, chronic, and disfiguring condition with no approved therapies, and the BEACON study is the first ever industry-sponsored placebo-controlled trial in the indication to read out positively.

BASEL, Switzerland and LONDON and NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reported its financial results for the third quarter ended December 31, 2025.

Capstone Copper Corp. ( CS:CA ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Daniel Sampieri - Vice President of Investor Relations Cashel Meagher - President, CEO & Director James Whittaker Raman Randhawa - CFO & Senior VP Wendy King - Senior VP of Risk & ESG, General Counsel and Corporate Secretary Peter Amelunxen - Senior Vice President of Technical Services Conference Call Participants Ralph Profiti - Stifel Nicolaus Canada Inc., Research Division Orest Wowkodaw - Scotiabank Global Banking and Markets, Research Division Dalton Baretto - Canaccord Genuity Corp., Research Division Fahad Tariq - Jefferies LLC, Research Division Daniel Morgan - Barrenjoey Markets Pty Limited, Research Division Craig Hutchison - TD Cowen, Research Division Adam Baker - Macquarie Research Anita Soni - CIBC Capital Markets, Research Division Marcio Farid Filho - Goldman Sachs Group, Inc., Research Division Presentation Operator " Daniel Sampieri Vice President of Investor Relations " Cashel Meagher President, CEO & Director " James Whittaker " Raman Randhawa CFO & Senior VP " Wendy King Senior VP of Risk & ESG, General Counsel and Corporate Secretary " Peter Amelunxen Senior Vice President of Technical Services " Ralph Profiti Stifel Nicolaus Canada Inc., Research Division " Stifel Nicolaus Canada Inc., Research Division Orest Wowkodaw Scotiabank Global Banking and Markets, Research Division " Scotiabank Global Banking and Markets, Research Division Dalton Baretto Canaccord Genuity Corp., Research Division " Canaccord Genuity Corp., Research Division Fahad Tariq Jefferies LLC, Research Division " Jefferies LLC, Research Division Daniel Morgan Barrenjoey Markets Pty Limited, Research Division " Barrenjoey Markets Pty Limited, Research Division Craig Hutchison TD Cowen, Research Division " TD Cowen, Research Division Adam Baker Macquarie Research " Macquarie Research Anita Soni CIBC Capital Markets, Research Division " CIBC Capital Markets, Research Division Marcio Farid Filho Goldman Sachs Group, Inc., Research Division " Goldman Sachs Group, Inc., Research Division Operator

Georgia's former prime minister Bidzina Ivanishvili on Monday urged a London court to uphold a $607 million Bermudan judgment he won against a Credit Suisse subsidiary over a long-running fraud committed by a former Credit Suisse adviser.

The latest plea deal caps a years-long investigation and underscores what federal officials described as a “massive criminal tax evasion scheme.”

UBS reportedly could settle a case this week involving Credit Suisse, which UBS acquired in 2023. The bank is set to pay hundreds of millions of dollars in the settlement of the case brought by the U.S. Department of Justice, The Wall Street Journal (WSJ) reported Thursday (Jan. 9), citing unnamed sources.

Investigators digging into archives at failed lender Credit Suisse found several Nazi-linked bank accounts that were never disclosed during 1990s-era probes that led to a $1 billion restitution agreement with survivors of the Holocaust.

Following is a timeline outlining the 168-year history of Credit Suisse Group, the Zurich-based bank that was formally absorbed on Friday by Swiss rival UBS after a 3 billion franc takeover last year.

The Goldman Sachs Group, Inc. (GS Quick QuoteGS - Free Report) plans to ramp up its lending services to private equity and asset managers, per Reuters. The bank also intends to expand internationally, filling the gaps created by the problems at regional banks and the recent sale of Credit Suisse.The private equity market has a strong potential to grow as private equity deals are expected to rise, driven by record-high fundraising. These loans are classified as short-term, typically secured by the assets of the borrowing firms and hence have a lesser risk attached to them. Hence, GS’ focus on the private equity market is a strategic fit.Asset-secured lending will allow GS to expand its financing business in fixed income, currency and commodities (FICC) and equities space. The move is in line with the company’s key focus on enhancing the stability of revenue generation in its global banking and markets divisions.In the past to seven years, Goldman's deposit base experienced tremendous growth. The bank is actively seeking to align its asset growth with this expansion. In 2023, GS took over a loan portfolio worth $15 billion from the failed Signature bank. This portfolio included loans to private equity firms and venture capital funds, which is a crucial part of its client base. These loans help manage a smooth flow of working capital for the bank, also known as capital call facilities or subscription line loans. Once Goldman strengthened its operations in the United States, the bank plans to expand its lending into Europe, the U.K. and Asia. They have already added staff in its Dallas and Bangalore offices to handle these loans.Markedly, Goldman decided to refocus on its core strengths of IB and trading operations while scaling back its consumer banking footprint and hence undertook a major business restructuring initiative. In first-quarter 2024, the company completed the sale of GreenSky, its home-improvement lending platform, to a consortium of investors. In second-half 2023, it sold its Personal Financial Management unit to Creative Planning. These are in line with its decision to focus on and grow core businesses where it showcased encouraging results given its strong leadership position, wide scale of operations and exceptional talent.In the past six months, the company’s shares have rallied 39.6% compared with the industry’s growth of 35.8%.Image Source: Zacks Investment ResearchGS currently sports a Zacks Rank #1 (Strong Buy). Apart from GS, major banks like JPMorgan Chase & Co. (JPM Quick QuoteJPM - Free Report) and The PNC Financial Services Group, Inc. (PNC Quick QuotePNC - Free Report) are also increasing their participation in the market worth $800 billion to $1 trillion. Also, JPM stepped up its lending functions after it acquired First Republic Bank in 2023. Similarly, in October 2023, PNC acquired loan commitments from Signature Bank worth approximately $16 billion. These efforts to further grow its loan balances are expected to offer support to the banks’ financials in the long run. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>

Switzerland put forward on Wednesday proposals for UBS and three other systemically relevant banks aimed at protecting the country from a repeat of last year's Credit Suisse collapse.

(CS)2AI is a 501(c)(6) not for profit organization Join as 13 experts share their analysis related to leading cybersecurity for operating technology (OT) & industrial control systems (ICS) industry reports. The findings from this year’s collaborative effort between CS2AI and KPMG International shed light on both the progress we’ve achieved and the persistent challenges we … The post Experts Share Insights From Leading ICS / OT Cybersecurity Reports in Upcoming Virtual Event appeared first on Hea...

Lex Greensill is facing up to a 15-year disqualification from running companies on the back of legal action taken by the UK's Insolvency Service. Following a probe into the directors of his failed firm, Greensill Capital, proceedings were opened up by the public body on behalf of the business secretary on Thursday.

The European Central Bank's chief supervisor on Thursday supported creating global standards for convertible bonds that were wiped out as part of Credit Suisse's rescue by rival UBS earlier this year.

UBS Group AG (NYSE:UBS) has started selling ‘Additional Tier 1' bonds again for the first time since its merger with Credit Suisse Group AG (NYSE:CS) caused the bond market to flail. The demand for the newly created debt instruments could signal renewed investor confidence after the Swiss bank's merger with Credit Suisse sent the market for debt into a spiral when a raft of bonds were written down.

Swiss National Bank Chairman Thomas Jordan said the central bank's interventions during the fall of Credit Suisse were "crucial" to avoid a "financial crisis."

BOSTON--(BUSINESS WIRE)---- $CS #classaction--Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Outset Medical Inc. ("Outset" or the "Company") (NASDAQ: OM), a medical technology company based in San Jose, California. About the Investigation On July 10, 2023, Bloomberg reported that Outset “shares decline[d] as much as 16% after receiving a warning letter from the US FDA raising two additional observations about its dialysis device, Tablo Hemodialysi.